Itron, Inc. (NASDAQ:ITRI) Shares Sold by Axa S.A.

Axa S.A. decreased its position in Itron, Inc. (NASDAQ:ITRI - Free Report) by 12.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 86,407 shares of the scientific and technical instruments company's stock after selling 12,741 shares during the quarter. Axa S.A. owned about 0.19% of Itron worth $9,382,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System lifted its stake in shares of Itron by 0.5% during the fourth quarter. Louisiana State Employees Retirement System now owns 21,800 shares of the scientific and technical instruments company's stock valued at $2,367,000 after buying an additional 100 shares during the period. Pinnacle Wealth Management Advisory Group LLC boosted its holdings in shares of Itron by 6.1% during the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 2,185 shares of the scientific and technical instruments company's stock worth $237,000 after purchasing an additional 125 shares during the last quarter. Summit Investment Advisors Inc. grew its position in shares of Itron by 3.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,726 shares of the scientific and technical instruments company's stock valued at $513,000 after purchasing an additional 140 shares during the period. GAMMA Investing LLC increased its stake in Itron by 15.6% in the fourth quarter. GAMMA Investing LLC now owns 1,177 shares of the scientific and technical instruments company's stock valued at $128,000 after purchasing an additional 159 shares during the last quarter. Finally, Mariner LLC lifted its position in Itron by 6.3% during the fourth quarter. Mariner LLC now owns 3,448 shares of the scientific and technical instruments company's stock worth $374,000 after buying an additional 204 shares during the period. 96.19% of the stock is currently owned by hedge funds and other institutional investors.

Itron Price Performance

Shares of NASDAQ ITRI opened at $107.55 on Tuesday. The company has a debt-to-equity ratio of 0.91, a current ratio of 3.36 and a quick ratio of 2.83. Itron, Inc. has a 1-year low of $90.11 and a 1-year high of $124.90. The company has a market capitalization of $4.90 billion, a price-to-earnings ratio of 22.04, a PEG ratio of 0.81 and a beta of 1.31. The business has a 50-day moving average of $104.37 and a 200-day moving average of $107.50.

Itron (NASDAQ:ITRI - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The scientific and technical instruments company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.22. Itron had a net margin of 9.37% and a return on equity of 19.03%. The company had revenue of $607.15 million during the quarter, compared to the consensus estimate of $608.86 million. During the same quarter last year, the company earned $1.24 earnings per share. Itron's revenue for the quarter was up .6% on a year-over-year basis. On average, equities analysts anticipate that Itron, Inc. will post 5.33 EPS for the current fiscal year.

Insider Buying and Selling at Itron

In other Itron news, Director Mary C. Hemmingsen sold 750 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $107.27, for a total transaction of $80,452.50. Following the sale, the director now owns 5,630 shares in the company, valued at $603,930.10. This represents a 11.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Christopher E. Ware sold 648 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $92.90, for a total value of $60,199.20. Following the sale, the senior vice president now directly owns 20,326 shares in the company, valued at approximately $1,888,285.40. This represents a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,037 shares of company stock valued at $385,815 in the last ninety days. Insiders own 1.45% of the company's stock.

Analysts Set New Price Targets

ITRI has been the topic of several research analyst reports. Guggenheim reissued a "buy" rating and issued a $133.00 target price on shares of Itron in a research report on Thursday, April 17th. Canaccord Genuity Group boosted their price objective on shares of Itron from $130.00 to $132.00 and gave the company a "buy" rating in a research note on Wednesday, February 26th. StockNews.com lowered Itron from a "strong-buy" rating to a "buy" rating in a research report on Saturday, March 1st. Oppenheimer boosted their price target on Itron from $124.00 to $131.00 and gave the company an "outperform" rating in a research report on Wednesday, February 26th. Finally, Piper Sandler cut their price objective on Itron from $124.00 to $121.00 and set a "neutral" rating on the stock in a report on Monday. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Itron currently has an average rating of "Moderate Buy" and an average price target of $127.36.

Itron Profile

Itron, Inc, a technology, solutions, and service company, provides end-to-end solutions that help manage energy, water, and smart city operations worldwide. It operates in three segments: Device Solutions, Networked Solutions, and Outcomes. The Device Solutions segment offers hardware products that are used for measurement, control, or sensing, such as standard gas, electricity, water, and communicating meters, as well as heat and allocation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.